Brii Biosciences Limited (HK:2137) has released an update.
Brii Biosciences Limited reassured stakeholders that VBI Vaccines Inc.’s insolvency will not materially impact its operations or financial performance. The company holds exclusive licenses for BRII-179 and PreHevbri in the Asia Pacific region and has already planned for the clinical studies and manufacturing transfers for BRII-179. Investors are reminded to exercise caution and seek professional advice when dealing with the company’s shares.
For further insights into HK:2137 stock, check out TipRanks’ Stock Analysis page.
